Crystal structures of pertussis toxin with NAD(+) and analogs provide structural insights into the mechanism of its cytosolic ADP-ribosylation activity

dc.contributor.authorSakari Moona
dc.contributor.authorTran Mai T
dc.contributor.authorRossjohn Jamie
dc.contributor.authorPulliainen Arto T
dc.contributor.authorBeddoe Travis
dc.contributor.authorLittler Dene R
dc.contributor.organizationfi=biolääketieteen laitos|en=Institute of Biomedicine|
dc.contributor.organization-code1.2.246.10.2458963.20.77952289591
dc.converis.publication-id175740287
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/175740287
dc.date.accessioned2022-10-27T12:19:49Z
dc.date.available2022-10-27T12:19:49Z
dc.description.abstractBordetella pertussis is the causative agent of whooping cough, a highly contagious respiratory disease. Pertussis toxin (PT), a major virulence factor secreted by B. pertussis, is an AB5-type protein complex topologically related to cholera toxin. The PT protein complex is internalized by host cells and follows a retrograde trafficking route to the endoplasmic reticulum, where it subsequently dissociates. The released enzymatic S1 subunit is then translocated from the endoplasmic reticulum into the cytosol and subsequently ADP-ribosylates the inhibitory alpha-subunits (G alpha i) of heterotrimeric G proteins, thus promoting dysregulation of G protein-coupled receptor signaling. However, the mechanistic details of the ADP-ribosylation activity of PT are not well understood. Here, we describe crystal structures of the S1 subunit in complex with nicotinamide adenine dinucleotide (NAD+), with NAD+ hydrolysis products ADP-ribose and nicotinamide, with NAD+ analog PJ34, and with a novel NAD+ analog formed upon S1 subunit crystallization with 3-amino benzamide and NAD+, which we name benzamide amino adenine dinucleotide. These crystal structures provide unprecedented insights into pre-and post-NAD+ hydrolysis steps of the ADP-ribosyltransferase activity of PT. We propose that these data may aid in rational drug design approaches and further development of PT-specific small-molecule inhibitors.
dc.identifier.eissn1067-8816
dc.identifier.jour-issn0021-9258
dc.identifier.olddbid174782
dc.identifier.oldhandle10024/157876
dc.identifier.urihttps://www.utupub.fi/handle/11111/34913
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0021925822003325
dc.identifier.urnURN:NBN:fi-fe2022081153867
dc.language.isoen
dc.okm.affiliatedauthorSakari, Moona
dc.okm.affiliatedauthorPulliainen, Arto
dc.okm.discipline3111 Biomedicineen_GB
dc.okm.discipline3111 Biolääketieteetfi_FI
dc.okm.internationalcopublicationinternational co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherELSEVIER
dc.publisher.countryUnited Statesen_GB
dc.publisher.countryYhdysvallat (USA)fi_FI
dc.publisher.country-codeUS
dc.relation.articlenumber101892
dc.relation.doi10.1016/j.jbc.2022.101892
dc.relation.ispartofjournalJournal of Biological Chemistry
dc.relation.issue5
dc.relation.volume298
dc.source.identifierhttps://www.utupub.fi/handle/10024/157876
dc.titleCrystal structures of pertussis toxin with NAD(+) and analogs provide structural insights into the mechanism of its cytosolic ADP-ribosylation activity
dc.year.issued2022

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
1-s2.0-S0021925822003325-main.pdf
Size:
3.12 MB
Format:
Adobe Portable Document Format